We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Oxurion NV | EU:OXUR | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0001 | 0.0001 | 0.0002 | 0.0001 | 0.0001 | 0.0001 | 23,025,000 | 16:40:00 |
From Jun 2024 to Jun 2024
Oxurion Announces Extraordinary General Shareholders’ Meeting
Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET).
This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolidation.
The convening notice and other documents pertaining to the shareholders’ meeting, can be consulted on Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NVPascal GhosonChief Executive Officerpascal.ghoson@oxurion.com | Backstage CommunicationJurgen VluijmansPartnerjurgen@backstagecom.be |
Attachment
1 Year Oxurion NV Chart |
1 Month Oxurion NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
